Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01096849
Other study ID # ACHN-490-002
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 13, 2010
Est. completion date April 3, 2012

Study information

Verified date August 2018
Source Achaogen, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a multi-center, multi-national, double-blind, randomized, comparator-controlled study of plazomicin administered intravenously compared with levofloxacin, a standard approved intravenous therapy for complicated urinary tract infection (cUTI) and acute pyelonephritis (AP).


Recruitment information / eligibility

Status Completed
Enrollment 145
Est. completion date April 3, 2012
Est. primary completion date April 3, 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Key Inclusion Criteria:

- Documented or suspected cUTI/AP with clinical signs and symptoms

- Normal kidney function defined as creatinine clearance (CLcr) of =60mL/min using Cockcroft-Gault formula

Key Exclusion Criteria:

- Acute bacterial prostatis, orchitis, epididymitis, or chronic bacterial prostatis

- Gross heanaturia requiring intervention other than study drug

- Urinary tract surgery within 7 days of randomization or during the study period

- A known nonrenal source of infection diagnosed within 7 days of randomization

- A corrected QT interval > 440 msec

- History of hearing loss with onset before the age of 40 years, sensorineural hearing loss, or family history of hearing loss

- Pregnant or breastfeeding women

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
levofloxacin

plazomicin

placebo


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Achaogen, Inc.

References & Publications (1)

Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01989-17. doi: 10.1128/AAC.01989-17. Print 2018 Apr. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population MBE was defined as documented eradication of all isolated pathogens. This was based on a urine culture, taken at the TOC visit that showed that all pathogens isolated at baseline at =10^5 colony forming unit(s) per milliliter (CFU/mL) were reduced to <10^4 CFU/mL. Day 1 to TOC (Day 12)
Primary Percentage of Patients Who Attained MBE at the TOC Visit in the Microbiologically Evaluable (ME) Population MBE was defined as documented eradication of all isolated pathogens. This was based on a urine culture, taken at the TOC visit that showed that all pathogens isolated at baseline at =10^5 CFU/mL were reduced to <10^4 CFU/mL. Day 1 to TOC (Day 12)
Primary Percentage of Patients With Treatment-Emergent Adverse Events (TEAE) An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered to be drug related. An AE (also referred to as an adverse experience) can be any unfavorable and unintended sign (eg, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, and it does not imply any judgment about causality. Adverse events also include the exacerbation or worsening of a condition present at screening other than the index infection for which the patient was enrolled in the study. A TEAE is any AE that newly appeared, increased in frequency, or worsened in severity following initiation of study drug. Day 1 to the end of study (Day 40)
Secondary Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at TOC Visit in the Intent-to-treat (ITT) Population Investigator's assessment criteria defined Clinical Cure as resolution of baseline clinical signs and symptoms of infection through the TOC visit.
The sponsor's assessment criteria was programmatically based on the investigator's assessment of participant clinical outcome, the number of days and doses of drug received and whether an antibiotic was administered.
Day 1 to TOC (Day 12)
Secondary Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the TOC Visit in the CE Population Investigator's assessment criteria defined Clinical Cure as a resolution of baseline clinical signs and symptoms of infection through the TOC visit.
The sponsor's assessment criteria was programmatically based on the investigator's assessment of participant clinical outcome, the number of days and doses of drug received and whether an antibiotic was administered.
Day 1 to TOC (Day 12)
Secondary Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the End of Treatment (EOT) Visit in the CE Population Investigator's assessment criteria defined Clinical Cure as a resolution of baseline clinical signs and symptoms of infection through the EOT visit.
The Sponsor's assessment criteria was programmatically based on the investigator's assessment of participant clinical outcome, the number of days and doses of drug received and whether an antibiotic was administered.
Day 1 to EOT (Day 5)
Secondary Percentage of Patients Who Attained MBE at the EOT Visit in the ME Population MBE was defined as documented eradication of all isolated pathogens. This was based on a urine culture, taken at the EOT visit that showed that all pathogens isolated at baseline at =10^5 CFU/mL were reduced to <10^4 CFU/mL. Day 1 to EOT (Day 5)
Secondary Percentage of Patients Who Attained MBE at the EOT Visit in the MITT Population MBE was defined as documented eradication of all isolated pathogens. This was based on a urine culture, taken at the EOT visit that showed that all pathogens isolated at baseline at =10^5 CFU/mL were reduced to <10^4 CFU/mL. Day 1 to EOT (Day 5)
Secondary Percentage of Patients Who Attained MBE at the TOC Visit in the ME Population by Baseline Pathogen MBE was defined as documented eradication of all isolated pathogens. This was based on a urine culture, taken at the TOC visit that showed that all pathogens isolated at baseline at =10^5 CFU/mL were reduced to <10^4 CFU/mL. Day 1 to TOC (Day 12)
Secondary Percentage of Patients Who Attained MBE at the TOC Visit in the ME Population Stratified by Infection Category MBE was defined as documented eradication of all isolated pathogens. This was based on a urine culture, taken at the TOC visit that showed that all pathogens isolated at baseline at =10^5 CFU/mL were reduced to <10^4 CFU/mL. Day 1 to TOC (Day 12)
Secondary Percentage of Patients Who Attained MBE at the TOC Visit in the ME Population by Country/Region MBE was defined as documented eradication of all isolated pathogens. This was based on a urine culture, taken at the TOC visit that showed that all pathogens isolated at baseline at =10^5 CFU/mL were reduced to <10^4 CFU/mL. Day 1 to TOC (Day 12)
Secondary Time (Days) to Resolution of Signs and Symptoms of cUTI and AP in the MITT Population Resolution of clinical signs and symptoms is defined as absence of all signs and symptoms present at baseline. Day 1 to End of Study (Day 40)
Secondary Time (Days) to Clinical Cure Based on Investigator's and Sponsor's Assessments in the MITT Population Investigator's assessment criteria defined Clinical Cure as a resolution of baseline clinical signs and symptoms of infection through the TOC visit.
The Sponsor's assessment criteria was programmatically based on the investigator's assessment of participant clinical outcome, the number of days and doses of drug received and whether an antibiotic was administered.
Day 1 to End of Study (Day 40)
Secondary Time (Days) to Defervescense in the MITT Population Defervescence is defined as the absence of fever <37.7 degrees Celsius and is assessed in patients who were afebrile at baseline. Day 1 to End of Study (Day 40)
Secondary Percentage of Patients Experiencing a Clinical Relapse or Microbiological Recurrence in the ME Population Patients who had a clinical relapse (defined as the return of clinical signs and symptoms requiring antibiotic therapy) or microbiological recurrence (defined as eradication of the original pathogen[s] at the TOC visit but regrowth at the level >10^5 CFU/mL by the LTFU [long term follow up] visit). Day 1 to LTFU (Day 40)
Secondary Percentage of Patients With a Superinfection or New Infection in the ME Population Superinfections are defined as a pathogen other than the one at baseline found in urine at =10^5 CFU/mL any time after the first infusion through EOT. New infections are defined as a pathogen other than the one at baseline found in urine at =10^5 CFU/mL any time after EOT. Day 1 to to End of Study (Day 40)
See also
  Status Clinical Trial Phase
Recruiting NCT05905055 - P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales Phase 3
Not yet recruiting NCT05060419 - Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections Phase 2
Recruiting NCT02537847 - Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli Phase 2
Completed NCT02166476 - Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Phase 3
Completed NCT03757234 - IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis Phase 2
Completed NCT06141395 - NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification
Recruiting NCT05887908 - Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis Phase 3
Completed NCT02420366 - Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Recruiting NCT04654507 - Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children Phase 3
Completed NCT04667195 - Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis
Completed NCT04686318 - Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis
Completed NCT03788967 - Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3
Recruiting NCT05674032 - Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis
Completed NCT02168946 - Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Phase 3
Not yet recruiting NCT03630081 - Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3
Completed NCT03445195 - Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections Phase 2
Completed NCT02486627 - A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) Phase 3
Completed NCT03477422 - CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria Phase 3
Recruiting NCT06059846 - A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3
Completed NCT01928433 - Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Phase 2